Released May 10, 2024, before the open
10-Q filed May 10, 2024, 40 days after period end · 0001558370-24-007695
Q1 2024 · 10-Q
Revenue$3.75M$3.75M −60.9% vs Q1 2023−64.3% vs Q4 2023
Net Income-$4.60M-$4.60M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.06-$0.06 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$4,856,000N/M
Operating Cash Flow$4,188,000N/M
Free Cash Flowderived$3,590,000N/M
Margins · derived
Operating margin-129.6%−103.9 pt vs Q1 2023
Net margin-122.6%−89.9 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $3.75M | $9.59M | $16.09M | $11.32M |
| Net Income | -$4.60M | -$3.13M | -$2.29M | -$5.48M |
| EPS Diluted | -$0.06 | -$0.05 | -$0.05 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR